Spotlight
Clinical
CME
Partners
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Joel Schuman, MD, discusses Glaucoma 360 and the Catalyst for a Cure
Joel Schuman, MD, FACS, director of the UPMC Eye Center at the University of Pittsburgh, discusses the upcoming Glaucoma 360 meeting and the Catalyst for a Cure. The meeting is planned for Feb. 5-7 in San Francisco. Both programs are part of Glaucoma Research Foundation's mission to prevent vision loss from glaucoma by investing in innovative research.
Joel Schuman, MD, FACS, director of the UPMC Eye Center at the University of Pittsburgh, discusses the upcoming Glaucoma 360 meeting and the Catalyst for a Cure. The meeting is planned for Feb. 5-7 in San Francisco. Both programs are part of Glaucoma Research Foundation's mission to prevent vision loss from glaucoma by investing in innovative research.
Related Videos
Related Content
